ALNY250117P290000
- 38.00
- 0.000.00%
Alnylam Pharmaceuticals Newsroom
(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest
Raymond James Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $298
Bernstein Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $310
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $295 to $400
Alnylam Pharma (ALNY) Gets a Buy From Bernstein
$1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Alnylam Shares Rise 8% On Preliminary Product Revenue Growth
Express News | Alnylam Pharmaceuticals Shares Are Trading Higher. The Company Reported Preliminary Results
Alnylam Pharmaceuticals To Present At J.P. Morgan Healthcare Conference; Webcast At 12:45 PM ET
Alnylam Pharmaceuticals Price Target Maintained With a $400.00/Share by HC Wainwright & Co.
Alnylam Shares Jump on Strong Revenue Forecast and Profit Outlook
ALNY Announces Preliminary 2024 Results, 2025 View & Pipeline Goals
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Using Debt Sensibly?
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $275 to $371
Express News | Alnylam Pharmaceuticals Inc - Net Product Revenues for Year of Over $1.6 Bln
Press Release: Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals
Express News | Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals
Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer -- Barrons.com
Bernstein Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $310
Alnylam Pharmaceuticals Is Maintained at Outperform by Bernstein